EVOTEC SE - SPON ADR
EVONASDAQTrading Snapshot
- Day Range
- $1.57 – $1.60
- 52-Week Range
- $1.33 – $4.19
- Volume (shares)
- 9,600.565
- Avg Volume (shares)
- —
- Shares Outstanding
- 355.2M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $757M
- Last Q Revenue
- $146M
- P/E Ratio
- -2.6
- P/S Ratio
- 0.7x
- EPS (TTM)
- $-0.55
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.2%
EVOTEC SE - SPON ADR
EVO
StockOtter · stockotter.spaceAbout EVOTEC SE - SPON ADR
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardPR NewswireHAMBURG, Germany, Oct. 15, 2026Will lead Evotec's g
Evotec (NASDAQ:EVO) Sees Unusually-High Trading Volume – Time to Buy?
Evotec AG (NASDAQ: EVO - Get Free Report) saw unusually-strong trading volume on Monday. 143,696 shares traded hands during mid-day trading, an increase of 43% from the previous session's volume of 100,289 shares. The st
Evotec Announces Chief Scientific Officer Transition
Evotec Announces Chief Scientific Officer TransitionPR NewswireHAMBURG, Germany, Sept. 29, 2026Dr. Cord Dohrmann to step down as of September 30, 2026Search ong
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflamma
Evotec: The Market Seems Split On The Company's Prospects, Buy
Evotec faces deteriorating fundamentals, with 1H26 revenue down nearly 20% and adjusted EBITDA turning sharply negative. I have withdrawn confidence in management's targets; valuation is now strictly on an as-is basis, w